VCYT vs. EXAS

Last updated Apr 1, 2026

Compare and contrast key facts about Veracyte, Inc. (VCYT) and Exact Sciences Corporation (EXAS).

Performance

VCYT vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Veracyte, Inc. (VCYT) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

VCYT vs. EXAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VCYT Veracyte, Inc.	-23.49%	6.31%	43.95%	15.93%	-42.40%	-15.82%	75.29%	121.94%	92.65%	-15.63%
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	20.10%	293.26%

Fundamentals

Market Cap VCYT : $2.62B EXAS : $19.91B
EPS VCYT : $0.83 EXAS : -$1.10
PS Ratio VCYT : 5.00 EXAS : 6.12
PB Ratio VCYT : 2.00 EXAS : 8.29
Total Revenue (TTM) VCYT : $517.15M EXAS : $3.25B
Gross Profit (TTM) VCYT : $362.53M EXAS : $2.26B
EBITDA (TTM) VCYT : $74.62M EXAS : $42.61M

Returns By Period

In the year-to-date period, VCYT achieves a -23.49% return, which is significantly lower than EXAS's 3.30% return. Over the past 10 years, VCYT has underperformed EXAS with an annualized return of 19.69%, while EXAS has yielded a comparatively higher 32.78% annualized return.

VCYT

• 1D: 5.81%
• 1M: -11.97%
• YTD: -23.49%
• 6M: -6.18%
• 1Y: 8.63%
• 3Y*: 13.04%
• 5Y*: -9.38%
• 10Y*: 19.69%

EXAS

• 1D: 0.00%
• 1M: 1.48%
• YTD: 3.30%
• 6M: 91.76%
• 1Y: 142.34%
• 3Y*: 16.54%
• 5Y*: -3.61%
• 10Y*: 32.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VCYT vs. EXAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VCYT

VCYT Risk / Return Rank: 46
VCYT Sharpe Ratio Rank: 47
VCYT Sortino Ratio Rank: 48
VCYT Omega Ratio Rank: 45
VCYT Calmar Ratio Rank: 46
VCYT Martin Ratio Rank: 46

EXAS

EXAS Risk / Return Rank: 96
EXAS Sharpe Ratio Rank: 96
EXAS Sortino Ratio Rank: 98
EXAS Omega Ratio Rank: 97
EXAS Calmar Ratio Rank: 92
EXAS Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VCYT vs. EXAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VCYT	EXAS	Difference
Sharpe ratio Return per unit of total volatility	0.16	2.80	-2.64
Sortino ratio Return per unit of downside risk	0.72	4.37	-3.64
Omega ratio Gain probability vs. loss probability	1.08	1.64	-0.56
Calmar ratio Return relative to maximum drawdown	0.18	4.40	-4.22
Martin ratio Return relative to average drawdown	0.41	15.32	-14.91
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VCYT vs. EXAS - Sharpe Ratio Comparison

The current VCYT Sharpe Ratio is 0.16, which is lower than the EXAS Sharpe Ratio of 2.80. The chart below compares the historical Sharpe Ratios of VCYT and EXAS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VCYT	EXAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.16	2.80	-2.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.15	-0.07	-0.08
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.32	0.55	-0.23
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.11	+0.01

Correlation

The correlation between VCYT and EXAS is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

VCYT vs. EXAS - Dividend Comparison

Neither VCYT nor EXAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VCYT vs. EXAS - Drawdown Comparison

The maximum VCYT drawdown since its inception was -81.19%, smaller than the maximum EXAS drawdown of -98.01%. Use the drawdown chart below to compare losses from any high point for VCYT and EXAS.

Drawdown Indicators

	VCYT	EXAS	Difference
Max Drawdown Largest peak-to-trough decline	-81.19%	-98.01%	+16.82%
Max Drawdown (1Y) Largest decline over 1 year	-39.23%	-29.56%	-9.67%
Max Drawdown (5Y) Largest decline over 5 years	-72.96%	-78.21%	+5.25%
Max Drawdown (10Y) Largest decline over 10 years	-81.19%	-80.42%	-0.77%
Current Drawdown Current decline from peak	-60.42%	-32.32%	-28.10%
Average Drawdown Average peak-to-trough decline	-48.28%	-49.80%	+1.52%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.00%	8.48%	+8.52%

Volatility

VCYT vs. EXAS - Volatility Comparison

Veracyte, Inc. (VCYT) has a higher volatility of 16.05% compared to Exact Sciences Corporation (EXAS) at 1.18%. This indicates that VCYT's price experiences larger fluctuations and is considered to be riskier than EXAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VCYT	EXAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.05%	1.18%	+14.87%
Volatility (6M) Calculated over the trailing 6-month period	40.87%	28.31%	+12.56%
Volatility (1Y) Calculated over the trailing 1-year period	55.36%	44.22%	+11.14%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.23%	54.53%	+9.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.38%	59.98%	+1.40%

Financials

VCYT vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between Veracyte, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VCYT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported a gross profit of 101.97M and revenue of 140.64M. Therefore, the gross margin over that period was 72.5%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

VCYT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported an operating income of 37.20M and revenue of 140.64M, resulting in an operating margin of 26.5%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

VCYT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported a net income of 41.15M and revenue of 140.64M, resulting in a net margin of 29.3%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.